Uniqure Nv Stock Fundamentals
| QURE Stock | USD 5.97 0.05 0.83% |
Uniqure NV fundamentals help investors to digest information that contributes to Uniqure NV's financial success or failures. It also enables traders to predict the movement of Uniqure Stock. The fundamental analysis module provides a way to measure Uniqure NV's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Uniqure NV stock.
Uniqure |
Uniqure NV Company Return On Equity Analysis
Uniqure NV's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Uniqure NV Return On Equity | -1.48 |
Most of Uniqure NV's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Uniqure NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Uniqure NV has a Return On Equity of -1.4757. This is 93.84% lower than that of the Biotechnology sector and 95.95% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Uniqure NV Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Uniqure NV's current stock value. Our valuation model uses many indicators to compare Uniqure NV value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Uniqure NV competition to find correlations between indicators driving Uniqure NV's intrinsic value. More Info.Uniqure NV is rated below average in return on equity category among its peers. It is rated fifth in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Uniqure NV by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Uniqure Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Uniqure NV's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Uniqure NV could also be used in its relative valuation, which is a method of valuing Uniqure NV by comparing valuation metrics of similar companies.Uniqure NV is currently under evaluation in return on equity category among its peers.
Uniqure Fundamentals
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (17.77) % | ||||
| Current Valuation | (76.65 M) | ||||
| Shares Outstanding | 48.74 M | ||||
| Shares Owned By Insiders | 9.23 % | ||||
| Shares Owned By Institutions | 81.95 % | ||||
| Number Of Shares Shorted | 3.17 M | ||||
| Price To Earning | 2.51 X | ||||
| Price To Book | 5.21 X | ||||
| Price To Sales | 10.26 X | ||||
| Revenue | 15.84 M | ||||
| Gross Profit | (87.37 M) | ||||
| EBITDA | (253.1 M) | ||||
| Net Income | (308.48 M) | ||||
| Cash And Equivalents | 500.52 M | ||||
| Cash Per Share | 10.71 X | ||||
| Total Debt | 138.41 M | ||||
| Debt To Equity | 0.29 % | ||||
| Current Ratio | 10.84 X | ||||
| Book Value Per Share | 1.15 X | ||||
| Cash Flow From Operations | (145.93 M) | ||||
| Short Ratio | 4.20 X | ||||
| Earnings Per Share | (4.95) X | ||||
| Target Price | 17.63 | ||||
| Number Of Employees | 480 | ||||
| Beta | 0.9 | ||||
| Market Capitalization | 293.43 M | ||||
| Total Asset | 831.69 M | ||||
| Retained Earnings | (890.41 M) | ||||
| Working Capital | 578.18 M | ||||
| Current Asset | 209.49 M | ||||
| Current Liabilities | 24.38 M | ||||
| Net Asset | 831.69 M |
About Uniqure NV Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Uniqure NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Uniqure NV using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Uniqure NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. The company also engages in developing AMT-130, a gene therapy that is in Phase III clinical study for the treatment of Huntingtons disease AMT-060, which is in Phase III clinical trial for the treatment of hemophilia B AMT-210, a product candidate for the treatment of Parkinsons disease AMT-260 for temporal lobe epilepsy AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimers disease and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands. Uniqure NV is traded on NASDAQ Exchange in the United States.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Uniqure NV is a strong investment it is important to analyze Uniqure NV's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Uniqure NV's future performance. For an informed investment choice regarding Uniqure Stock, refer to the following important reports:Check out Uniqure NV Piotroski F Score and Uniqure NV Altman Z Score analysis. For information on how to trade Uniqure Stock refer to our How to Trade Uniqure Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Uniqure NV. If investors know Uniqure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Uniqure NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Uniqure NV is measured differently than its book value, which is the value of Uniqure that is recorded on the company's balance sheet. Investors also form their own opinion of Uniqure NV's value that differs from its market value or its book value, called intrinsic value, which is Uniqure NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Uniqure NV's market value can be influenced by many factors that don't directly affect Uniqure NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Uniqure NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if Uniqure NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Uniqure NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.